The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …

Background: Epicardial adipose tissue (EAT) accumulation is thought to play a role in the
pathophysiology of heart failure (HF) with mid-range and preserved ejection fraction, but its …

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity with
complex pathophysiology and manifestations. Phenomapping is the process of applying …

Heart failure (HF) with preserved ejection fraction (HFpEF) is currently the predominant form
of HF with a dramatic increase in risk with age. Low‐grade inflammation, as occurs with …

Heart failure (HF) with preserved ejection (HFpEF) constitutes a large and growing
proportion of patients with HF around the world, and is now responsible for more than half of …

Background: Inflammation may play a role in the pathophysiology of heart failure with
preserved ejection fraction. We examined whether circulating levels of interleukin-6 identify …

BACKGROUND: Pulmonary hypertension (PH) in heart failure with preserved ejection
fraction (HFpEF) is a common and highly morbid syndrome, but mechanisms driving PH …

Abstract Background Interleukin (IL)-6 is a central inflammatory mediator and potential
therapeutic target in heart failure (HF). Prior studies have shown that IL-6 concentrations are …

Obesity causes extracellular matrix (ECM) remodelling which can develop into serious
pathology and fibrosis, having metabolic effects in insulin-sensitive tissues. The ECM …